Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025
ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA is a Class 2 review, which results in a six-month review period from the date of resubmission. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025. ONS-5010, if approved, will be branded as LYTENAVA™ (bevacizumab-vikg) in the United States for the treatment of wet AMD and is expected to receive 12 years of regulatory exclusivity.
'Our team has worked diligently to advance our development and regulatory strategies for ONS-5010 to get to this point and we are proud of the continued progress we have been able to achieve,' commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. 'This BLA acceptance and PDUFA date are significant milestones in our continued mission to offer clinicians and their patients the first and only on-label, ophthalmic bevacizumab to treat wet AMD. We are committed to bringing an ophthalmic bevacizumab to market in the United States and are continuing our activities for potential commercialization.'
The ONS-5010 BLA resubmission was based on the efficacy and safety demonstrated in NORSE EIGHT, as well as additional chemistry, manufacturing and controls (CMC) information requested by the FDA. As previously announced, following Type A meetings with the FDA in Q4 CY2023 to address the ONS-5010 Complete Response Letter (CRL), the FDA informed Outlook Therapeutics that, in order to meet the FDA's requirement for a second adequate and well-controlled clinical trial of ONS-5010, it could conduct a non-inferiority study evaluating ONS-5010 versus ranibizumab in a 12 week study of treatment naïve patients with a primary efficacy endpoint at 8 weeks (NORSE EIGHT). Outlook Therapeutics believes that the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
ONS-5010 / LYTENAVA™ is an ophthalmic formulation of bevacizumab for the treatment of wet AMD. LYTENAVA™ (bevacizumab gamma) is the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.
In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF's biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection, the binding of bevacizumab to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as 'anticipate,' 'believe,' 'continue,' 'expect,' 'may,' 'plan,' 'potential,' 'will,' or 'would' the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, Outlook Therapeutics' ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA in the resubmitted BLA, expectations concerning decisions of regulatory bodies and the timing thereof, including the PDFUA review goal date, expectations concerning the therapeutic potential of LYTENAVA™ as a treatment of wet AMD, ONS-5010/LYTENAVA™'s potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States, Outlook Therapeutics' plans for commercial launch of LYTENAVA™ in the UK and EU and timing thereof, Outlook Therapeutics' commercialization strategy, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics' resources, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the SEC on December 27, 2024, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Jenene Thomas
JTC Team, LLC
T: 908.824.0775
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Bentley is in limbo as tariffs remain unclear: What to know
The EU is looking to enact a 10% tariff across the board. Additionally, Bentley (VWAGY) is holding back inventory as tariff uncertainty clouds US import plans. Yahoo Finance Senior Reporter Pras Subramanian explains how this affects automakers and how the lack of a finalized US–UK deal is forcing Bentley to go month-to-month on its pricing strategy. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Meanwhile, the European Union weighing a 10% tariff deal as President Trump's July deadline now looms. For more what this means for carmakers, let's get to our senior autos reporter, prize Sumerian prize. Yeah, I mean, this is kind of a big deal for European automakers like BMW and Mercedes, that that to bring that down the sector tariffs is 25% to 10% will be a huge deal for them, uh, based on the fact that so many of their cars are sold here. Uh, I mean, but, you know, the UK has a deal already supposedly with, with, uh, with the US and I spoke to the Bentley CEO about this, and they said, hold on, there's actually no details yet. Uh, the deal is supposedly been agreed to, but, uh, the UK government's still waiting for paperwork and an actual deal terms from the US government and, and, uh, UK government said it might take a few weeks still. So I spoke to the CEO about this, and he said, basically, since we don't have the deal actually, the terms yet and signed So he's saying I don't know. He's saying I just have a world of uncertainty I'm navigating. Yeah, so they, exactly, because they, they, you know, last month, they made the deal, made the announcement, but the deal has not actually been hasn't been signed yet, or come through yet. So he told me a few things they're doing, basically they're working month to month here on policy, uh, price protecting through the month of June, uh, people who have custom orders in place, they'll they'll honor those pricing agreements and they'll bring the cars in, but further inventory is going to be held in the UK until, uh, until further notice and, and basically, they just can't bring those vehicles in until they know what their exposure is going to be, because it could be a lot more, it could be a lot less who knows. So keeping it there, uh, they won't make any more decisions till next month. So month to month, we'll keep an eye on that, but they also have a new car out, new Bentayga Speed, SUVs are top selling SUV. I mean, the speed version is a VA powered truck. How much is that going to run us? Yeah, that's a big question. Around 300 grand, probably, but it's going to be only gas powered. It's just a change for them because they've been going heavily into hybrid, but they say, hey, you know what, our buyers want this option, and it'll be a very special car. So they're going to do it. I would assume that Bentley has a decent amount of pricing power at that level of customer that if they do end up if they get more clarity around the effect of the tariffs, if that's going to increase their costs that they can pretty easily pass that on to their customers or I mean, 10% is not that big of a jump from, let's say, 25. So a $300,000 car, you're talking about $30,000. So how much of that's going to go to the client and versus them? Half, uh, more than half, and that's part of the question they have to sort of answer themselves. But I think you're right, I think they, it's, it's, it's not a, it's not a fully elastic good, right? There is some, uh, ability to kind of waver here with pricing, but they can't go too far, right? Because margins are, I think the last, last year, they were around, uh, 14%, right? So there's only so much you can play with. And that's been coming down from 20 the year before. So that's the big question. Even if you're rich, you still want to feel like you're getting a good deal. That's why you have all the money. You don't pay, you don't need to. There you go. All right, thanks so much, Pras. Inicia sesión para acceder a tu portafolio
Yahoo
35 minutes ago
- Yahoo
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know
Urgent Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know originally appeared on Parade. From morning coffee to vitamins, there are plenty of must-have's that help set up a successful daily routine. In fact, according to Johns Hopkins Medicine, a whopping 50% of American adults take a multivitamin, vitamin or mineral supplement regularly. If you happen to be part of that group of consistent vitamin takers though, you'll want to double check your medicine cabinet. Because one lot of B12 vitamins is being voluntarily recalled by Vita Warehouse Corp thanks to the potential presence of undeclared peanuts. 🍳 SIGN UP to get delicious recipes, handy kitchen hacks & fun food news in our daily Pop Kitchen newsletter 🍳 Considering these Welby, Berkley Jensen and VitaGlobe vitamins are also sold by some of the most popular retailers like ALDI and Amazon, there's a good chance shoppers may unknowingly have a bottle. According to a company announcement shared by the U.S. Food and Drug Administration, this recall affects one lot of Aldi Welby B12 Energy Support gummies, Berkely Jensen B12 Vitamin gummies and Vitamin B12 Extra Strength gummies. The FDA warns that 'people with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions,' if they take these no illnesses or allergic reactions have been reported so far. The undeclared peanuts were actually discovered by ALDI. After conducting routine testing per its standard protocol, one of the tests 'indicated a potential presence of a peanut allergen.' While internal testing done by Vita Warehouse Corp. 'verified the absence of peanuts," the recall was issued out of caution. So, how do you know for sure if you have one of the affected vitamins? There are a few key ways. First, these were sold nationwide at ALDI and BJ's in-store. They were also sold online on ALDI's, BJ's and VitaGlobe's websites and on Amazon. Additionally, each product will have an expiration date of October 2026. The company says that each of the affected vitamins have the following UPC codes and Lot numbers. Aldi Welby: clear bottle with white cap, using green, red, and white labeling. UPC Code: 4099100290868 Lot #: 248046601* Berkeley Jensen: clear bottle with white cap, using red and pink labeling. UPC Code: 888670132487 Lot #: 248046601* VitaGlobe: clear bottle with white cap, using white and red labeling. UPC Code: 850005214670 Lot #: 248046601* The Lot codes and expiration dates can all be found printed on the bottom of each bottle. The FDA urges consumers who have a peanut allergy to return or throw away any affected vitamins ASAP. Customers who do return them can expect a full refund from the original store of purchase. Those with further questions can contact Vita Warehouse at 1-855-214-0100 Monday through Friday from 7:30 am to 4 pm Nationwide Recall Issued on This Popular Item Sold at Aldi—Here's What to Know first appeared on Parade on Jun 18, 2025 This story was originally reported by Parade on Jun 18, 2025, where it first appeared.
Epoch Times
2 hours ago
- Epoch Times
FDA Approves HIV-Prevention Drug That Nearly Eliminated the Virus's Spread in Clinical Trials
Gilead Sciences announced June 18 that the Food and Drug Administration (FDA) has approved its twice-a-year shot to prevent HIV, with company executives touting the medication as a 'very real opportunity' at ending the HIV epidemic. In a
